A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age

Basilea Pharmaceutica

Status and phase

Completed

Phase 1

Conditions

Streptococcal Infections

Staphylococcal Skin Infections

Treatments

Drug: Ceftobiprole

Study type

Interventional

Funder types

Industry

Identifiers

NCT01026636

CR012304

CSI-1001 (Other Identifier)

Details and patient eligibility

About

This study will assess the pharmacokinetics (how drugs are absorbed, distributed in the body and removed over time) and safety of a single dose of ceftobiprole in pediatric patients undergoing treatment with systemic antibiotics and may be used to guide dosing recommendations for ceftobiprole in children.

Full description

This purpose of this study will be to assess the pharmacokinetics (how drugs are absorbed, distributed in the body and removed over time) and safety of a single dose of ceftobiprole in pediatric patients undergoing treatment with systemic antibiotics and may be used to guide dosing recommendations for ceftobiprole in children. This study is an open-label (all patients will know the identity of the drug) single-dose, pharmacokinetic study in infants and children =3 months to <18 years of age who are medically stable as judged by the clinical investigator and require therapy with antibiotics. Patients will be given a 2-hour i.v. infusion (given directly into the vein) of 7, 10, or 15 mg/kg ceftobiprole. The study population will be grouped according to the following 4 age groups: =12 to <18 years of age; =6 to <12 years of age; =2 to <6 years of age; and =3 months to <2 years of age. Every attempt will be made to include patients of both sexes in each age group. Safety evaluations will include clinical laboratory tests (hematology, serum chemistry, and urinalysis), pregnancy testing, vital signs, physical examination, monitoring of adverse events, and recording of concomitant medications. Patients will be given a single 2-hour i.v. (given directly into the vein) infusion of ceftobiprole. The total duration of the study is approximately 18 days, including screening and posttreatment.

Enrollment

64 patients

Sex

All

Ages

3 months to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Infants (=3 months to <2 years of age) must have been born at =36 weeks of gestation
Documented or presumed, or be at risk for, bacterial infection(s) and receiving systemic antibiotic therapy
Stable medical condition

Exclusion criteria

History of drug allergy or hypersensitivity to ß-lactam antibiotics such as penicillins, cephalosporins, or carbapenems
History of clinically significant cardiac arrhythmia, cystic fibrosis, chronic lung disease associated with abnormal pulmonary function, acute or chronic arthritis
History of infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)